← Human Trials & Peer-Reviewed Studies
Acute effects of glucagon-like peptide-1, GLP-1(9-36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
Plain-language guide to PMID 28235974 (2017): double-blind randomized controlled trial study of Exenatide.
Key Facts
- PMID
- 28235974
- Journal
- Physiological reports
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Bremholm L et al. (7 authors)
- DOI
- 10.14814/phy2.13102
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in this randomized controlled trial publication.
To investigate the influence of GLP-1 receptor agonism on mesenteric and renal blood flow and cardiovascular parameters, the researchers carried out a double-blinded randomized clinical trial.
Why It Was Studied
The researchers hypothesized that GLP-1 also stimulates intestinal blood flow and that this would impact on the overall digestive and cardiovascular effects of the hormone.
A total of eight healthy volunteers received high physiological subcutaneous injections of GLP-1, GLP-19-36 amide (bioactive metabolite), exenatide (stable GLP-1 agonist), or saline on four separate days.
Who Took Part
By PubMed's age tags, the people studied were young adults and adults, both men and women.
How the Study Was Run
In design terms this was a randomized and double-blind study.
The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.
As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.
Blood flow in mesenteric, celiac, and renal arteries was measured by Doppler ultrasound.
Blood pressure, heart rate, cardiac output, and stroke volume were measured continuously using an integrated system.
What Was Measured
The researchers hypothesized that GLP-1 also stimulates intestinal blood flow and that this would impact on the overall digestive and cardiovascular effects of the hormone.
Topics PubMed links to this paper include Biomarkers, Blood Glucose, Blood Pressure, Cardiac Output, Exenatide, Glucagon-Like Peptide 1 and Healthy Volunteers.
Author keywords: glucagon like‐peptide‐1 and mesenteric blood flow.
What This Means in Plain Language
The paper is a randomized and double-blind study of Exenatide.
The publication is from 2017 (Physiological reports), a journal based in United States.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.